Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 1-2/2016

01.01.2016 | original article

Liver fatty acid-binding protein as a diagnostic marker for non-alcoholic fatty liver disease

verfasst von: MD Erdem Akbal, MD Erdem Koçak, MD Assist. Prof. Ömer Akyürek, MD Seyfettin Köklü, MD Hikmetullah Batgi, MD Mehmet Şenes

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 1-2/2016

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Background and aims

Liver fatty acid-binding protein (L-FABP) is a small cytoplasmic protein. The aim of the current study was to investigate L-FABP levels and to determine their diagnostic value for non-alcoholic fatty liver disease (NAFLD).

Methods

We enrolled in this study 24 consecutive patients with NAFLD who were diagnosed with elevated transaminases and with steatosis by ultrasonograph. The control group consisted of 22 healthy control subjects matched for age and gender. Serum levels of L-FABP were determined by enzyme-linked immunosorbent assay.

Results

L-FABP levels in NAFLD patients were higher than in the control group (levels were 41,976 ± 18,998 and 17048 ± 5021 pg/mL, respectively). A strong correlation was found between serum L-FABP concentrations and aspartate aminotransferase, alanine aminotransferase, body mass index, glucose and γ-glutamyltransferase levels. A level of 284,000 pg/mL L-FABP had 73 % sensitivity and 100 % specificity. Positive and negative predictive values for L-FABP were 100  and 79%, respectively.

Conclusions

Serum L-FABP can be considered as a new diagnostic marker for detecting non-alcoholic fatty liver disease.
Literatur
1.
Zurück zum Zitat Chitturi S, Farrell G, George J. Non-alcoholic steatohepatitis in the Asia-Pacific region: future shock? J Gastroenterol Hepatol. 2004;1:368–74. CrossRef Chitturi S, Farrell G, George J. Non-alcoholic steatohepatitis in the Asia-Pacific region: future shock? J Gastroenterol Hepatol. 2004;1:368–74. CrossRef
2.
Zurück zum Zitat Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917–23. CrossRefPubMed Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917–23. CrossRefPubMed
3.
Zurück zum Zitat Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113–21. CrossRefPubMed Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113–21. CrossRefPubMed
4.
Zurück zum Zitat Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–9. CrossRefPubMed Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–9. CrossRefPubMed
5.
Zurück zum Zitat Angelico F, Del Ben M, Conti R, Francioso S, Feole K, Fiorello S, et al. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2005;90(3):1578–82. CrossRefPubMed Angelico F, Del Ben M, Conti R, Francioso S, Feole K, Fiorello S, et al. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2005;90(3):1578–82. CrossRefPubMed
6.
Zurück zum Zitat Lee D, Wada K, Taniguchi Y, Al-Shareef H, Masuda T, Usami Y, Aikawa T, Okura M, Kamisaki Y, Kogo M. Expression of fatty acid binding protein 4 is involved in the cell growth of oral squamous cell carcinoma. Oncol Rep. 2014;31(3):1116–20. PubMed Lee D, Wada K, Taniguchi Y, Al-Shareef H, Masuda T, Usami Y, Aikawa T, Okura M, Kamisaki Y, Kogo M. Expression of fatty acid binding protein 4 is involved in the cell growth of oral squamous cell carcinoma. Oncol Rep. 2014;31(3):1116–20. PubMed
7.
Zurück zum Zitat Jeon WS, Park SE, Rhee EJ, Park CY, Oh KW, Park SW, Lee WY. Association of serum adipocyte-specific fatty acid binding protein with fatty liver index as a predictive indicator of nonalcoholic fatty liver disease. Endocrinol Metab (Seoul). 2013;28(4):283–7. CrossRef Jeon WS, Park SE, Rhee EJ, Park CY, Oh KW, Park SW, Lee WY. Association of serum adipocyte-specific fatty acid binding protein with fatty liver index as a predictive indicator of nonalcoholic fatty liver disease. Endocrinol Metab (Seoul). 2013;28(4):283–7. CrossRef
8.
Zurück zum Zitat Kim YC, Cho YK, Lee WY, Kim HJ, Park JH, Park DI, Sohn CI, Jeon WK, Kim BI, Park SE, Rhee EJ, Park CY, Oh KW, Park SW, Kim SW, Ryu SH. Serum adipocyte-specific fatty acid-binding protein is associated with nonalcoholic fatty liver disease in apparently healthy subjects. J Nutr Biochem. 2011;22(3):289–92. CrossRefPubMed Kim YC, Cho YK, Lee WY, Kim HJ, Park JH, Park DI, Sohn CI, Jeon WK, Kim BI, Park SE, Rhee EJ, Park CY, Oh KW, Park SW, Kim SW, Ryu SH. Serum adipocyte-specific fatty acid-binding protein is associated with nonalcoholic fatty liver disease in apparently healthy subjects. J Nutr Biochem. 2011;22(3):289–92. CrossRefPubMed
9.
Zurück zum Zitat Masetti M, Bianchi G, Gianotti G, Giovagnoli M, Vizioli L, Zorzi V, Rossi V, Forti P, Zoli M. Adipocyte-fatty acid binding protein and non-alcoholic fatty liver disease in the elderly. Aging Clin Exp Res. 2014;26(3):241–7. CrossRefPubMed Masetti M, Bianchi G, Gianotti G, Giovagnoli M, Vizioli L, Zorzi V, Rossi V, Forti P, Zoli M. Adipocyte-fatty acid binding protein and non-alcoholic fatty liver disease in the elderly. Aging Clin Exp Res. 2014;26(3):241–7. CrossRefPubMed
10.
Zurück zum Zitat Ozbek M, Erdogan M, Dogan M, et al. Serum heart-type fatty acid binding protein (H-FABP) levels in acromegaly patients. J Endocrinol Invest. 2011;34:576–9. PubMed Ozbek M, Erdogan M, Dogan M, et al. Serum heart-type fatty acid binding protein (H-FABP) levels in acromegaly patients. J Endocrinol Invest. 2011;34:576–9. PubMed
11.
Zurück zum Zitat Akbal E, Ozbek M, Gunes F, et al. Serum heart type fatty acid binding protein levels in metabolic syndrome. Endocrine. 2009;36:433–7. CrossRefPubMed Akbal E, Ozbek M, Gunes F, et al. Serum heart type fatty acid binding protein levels in metabolic syndrome. Endocrine. 2009;36:433–7. CrossRefPubMed
12.
Zurück zum Zitat Oktay B, Akbal E, Firat H, et al. Evaluation of the relationship between heart type fatty acid binding protein levels and the risk of cardiac damage in patients with obstructive sleep apnea syndrome. Sleep Breath. 2008;12:223–8. CrossRefPubMed Oktay B, Akbal E, Firat H, et al. Evaluation of the relationship between heart type fatty acid binding protein levels and the risk of cardiac damage in patients with obstructive sleep apnea syndrome. Sleep Breath. 2008;12:223–8. CrossRefPubMed
13.
Zurück zum Zitat Negishi K, Noiri E, Doi K, et al. Monitoring of urinary L-type fatty acid-binding protein predicts histological severity of acute kidney injury. Am J Pathol. 2009;174:1154–9. PubMedCentralCrossRefPubMed Negishi K, Noiri E, Doi K, et al. Monitoring of urinary L-type fatty acid-binding protein predicts histological severity of acute kidney injury. Am J Pathol. 2009;174:1154–9. PubMedCentralCrossRefPubMed
14.
Zurück zum Zitat Nielsen SE, Sugaya T, Hovind P, et al. Urinary liver-type fatty acidbinding protein predicts progression to nephropathy in type 1 diabetic patients. Diabetes Care. 2010;33:1320–4. PubMedCentralCrossRefPubMed Nielsen SE, Sugaya T, Hovind P, et al. Urinary liver-type fatty acidbinding protein predicts progression to nephropathy in type 1 diabetic patients. Diabetes Care. 2010;33:1320–4. PubMedCentralCrossRefPubMed
15.
Zurück zum Zitat Sasaki H, Kamijo-Ikemori A, Sugaya T, et al. Urinary fatty acids and liver-type fatty acid binding protein in diabetic nephropathy. Nephron Clin Pract. 2009;112:148–56. CrossRef Sasaki H, Kamijo-Ikemori A, Sugaya T, et al. Urinary fatty acids and liver-type fatty acid binding protein in diabetic nephropathy. Nephron Clin Pract. 2009;112:148–56. CrossRef
16.
Zurück zum Zitat Guzmán C, Benet M, Pisonero-Vaquero S, Moya M, García-Mediavilla MV, Martínez-Chantar ML, González-Gallego J, Castell JV, Sánchez-Campos S, Jover R. The human liver fatty acid binding protein (FABP1) gene is activated by FOXA1 and PPARα; and repressed by C/EBPα: Implications in FABP1 down-regulation in nonalcoholic fatty liver disease. Biochim Biophys Acta. 2013;1831(4):803–18. CrossRefPubMed Guzmán C, Benet M, Pisonero-Vaquero S, Moya M, García-Mediavilla MV, Martínez-Chantar ML, González-Gallego J, Castell JV, Sánchez-Campos S, Jover R. The human liver fatty acid binding protein (FABP1) gene is activated by FOXA1 and PPARα; and repressed by C/EBPα: Implications in FABP1 down-regulation in nonalcoholic fatty liver disease. Biochim Biophys Acta. 2013;1831(4):803–18. CrossRefPubMed
17.
Zurück zum Zitat Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov. 2008;7:489–503. PubMedCentralCrossRefPubMed Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov. 2008;7:489–503. PubMedCentralCrossRefPubMed
18.
Zurück zum Zitat Özenirler S, Degertekin CK, Erkan G, Elbeğ Ş, Tuncer C, Kandilc U, Akyol G. Serum liver fatty acid binding protein shows good correlation with liver histology in NASH. Hepatogastroenterology. 2013;60(125):1095–100. PubMed Özenirler S, Degertekin CK, Erkan G, Elbeğ Ş, Tuncer C, Kandilc U, Akyol G. Serum liver fatty acid binding protein shows good correlation with liver histology in NASH. Hepatogastroenterology. 2013;60(125):1095–100. PubMed
19.
20.
Zurück zum Zitat Pelsers MM, Morovat A, Alexander GJ, et al. Liver fatty acid-binding protein as a sensitive serum marker of acute hepatocellular damage in liver transplant recipients. Clin Chem. 2002;48:2055–7. PubMed Pelsers MM, Morovat A, Alexander GJ, et al. Liver fatty acid-binding protein as a sensitive serum marker of acute hepatocellular damage in liver transplant recipients. Clin Chem. 2002;48:2055–7. PubMed
21.
Zurück zum Zitat Ishimitsu T, Ohta S, Saito M, et al. Urinary excretion of liver fatty acid-binding protein in health-check participants. Clin Exp Nephrol. 2005;9:34–9. CrossRefPubMed Ishimitsu T, Ohta S, Saito M, et al. Urinary excretion of liver fatty acid-binding protein in health-check participants. Clin Exp Nephrol. 2005;9:34–9. CrossRefPubMed
22.
Zurück zum Zitat Akbal E, Köklü S, Koçak E, Cakal B, Güneş F, Başar O, Tuna Y, Senes M. Liver fatty acid-binding protein is a diagnostic marker to detect liver injury due to chronic hepatitis C infection. Arch Med Res. 2013;44(1):34–8. doi:10.1016/j.arcmed.2012.11.007. CrossRefPubMed Akbal E, Köklü S, Koçak E, Cakal B, Güneş F, Başar O, Tuna Y, Senes M. Liver fatty acid-binding protein is a diagnostic marker to detect liver injury due to chronic hepatitis C infection. Arch Med Res. 2013;44(1):34–8. doi:10.1016/j.arcmed.2012.11.007. CrossRefPubMed
23.
Zurück zum Zitat Hamaguchi M, Kojima T, Itoh Y, Harano Y, Fujii K, Nakajima T, Kato T, Takeda N, Okuda J, Ida K, Kawahito Y, Yoshikawa T, Okanoue T. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol. 2007;102(12):2708–15. CrossRefPubMed Hamaguchi M, Kojima T, Itoh Y, Harano Y, Fujii K, Nakajima T, Kato T, Takeda N, Okuda J, Ida K, Kawahito Y, Yoshikawa T, Okanoue T. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol. 2007;102(12):2708–15. CrossRefPubMed
24.
Zurück zum Zitat Pelsers MM, Morovat A, Alexander GJ, et al. Liver fatty acid-binding protein as a sensitive serum marker of acute hepatocellular damage in liver transplant recipients. Clin Chem. 2002;48:2055–7. PubMed Pelsers MM, Morovat A, Alexander GJ, et al. Liver fatty acid-binding protein as a sensitive serum marker of acute hepatocellular damage in liver transplant recipients. Clin Chem. 2002;48:2055–7. PubMed
25.
Zurück zum Zitat Chen A, Tang Y, Davis V, Hsu FF, Kennedy SM, Song H, Turk J, Brunt EM, Newberry EP, Davidson NO. Liver fatty acid binding protein (L-FABP) modulates murine stellate cell activation and diet-induced nonalcoholic fatty liver disease. Hepatology. 2013;57(6):2202–12. PubMedCentralCrossRefPubMed Chen A, Tang Y, Davis V, Hsu FF, Kennedy SM, Song H, Turk J, Brunt EM, Newberry EP, Davidson NO. Liver fatty acid binding protein (L-FABP) modulates murine stellate cell activation and diet-induced nonalcoholic fatty liver disease. Hepatology. 2013;57(6):2202–12. PubMedCentralCrossRefPubMed
26.
Zurück zum Zitat van den Broek MA, Bloemen JG, Dello SA, et al. Randomized controlled trial analyzing the effect of 15 or 30 min intermittent Pringle maneuver on hepatocellular damage during liver surgery. J Hepatol. 2011;55:337–45. CrossRefPubMed van den Broek MA, Bloemen JG, Dello SA, et al. Randomized controlled trial analyzing the effect of 15 or 30 min intermittent Pringle maneuver on hepatocellular damage during liver surgery. J Hepatol. 2011;55:337–45. CrossRefPubMed
27.
Zurück zum Zitat Van de Poll MC, Derikx JP, Buurman WA, et al. Liver manipulation causes hepatocyte injury and precedes systemic inflammation in patients undergoing liver resection. World J Surg. 2007;31:2033–8. PubMedCentralCrossRefPubMed Van de Poll MC, Derikx JP, Buurman WA, et al. Liver manipulation causes hepatocyte injury and precedes systemic inflammation in patients undergoing liver resection. World J Surg. 2007;31:2033–8. PubMedCentralCrossRefPubMed
Metadaten
Titel
Liver fatty acid-binding protein as a diagnostic marker for non-alcoholic fatty liver disease
verfasst von
MD Erdem Akbal
MD Erdem Koçak
MD Assist. Prof. Ömer Akyürek
MD Seyfettin Köklü
MD Hikmetullah Batgi
MD Mehmet Şenes
Publikationsdatum
01.01.2016
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 1-2/2016
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-014-0680-8